切换至 "中华医学电子期刊资源库"
高级检索
中华结直肠疾病电子杂志

中华结直肠疾病电子杂志 ›› 2022, Vol. 11 ›› Issue (02) : 163 -167. doi: 10.3877/cma.j.issn.2095-3224.2022.02.012

经验交流

10 mm~20 mm非转移性直肠神经内分泌肿瘤完整切除率的多因素分析
朱信强1, 黄海龙2, 蒋学通1, 邢春根3,†()   
  1. 1. 223800　徐州医科大学附属宿迁医院普外科；215004　苏州大学附属第二医院普外科
    2. 223800　徐州医科大学附属宿迁医院普外科
    3. 215004　苏州大学附属第二医院普外科
  • 收稿日期:2021-08-11 出版日期:2022-04-25
  • 通信作者: 邢春根
  • 基金资助:
    2019年度宿迁市产业发展引导资金（科技创新专项———重点研发计划）(S201913)

Multifactor analysis of complete resection rate of 10 mm~20 mm nonmetastatic rectal neuroendocrine tumor

Xinqiang Zhu1, Hailong Huang2, Xuetong Jiang1, Chungen Xing3,†()   

  1. 1. Department of General Surgery, the Affiliated Suqian Hospital of Xuzhou Medical University, Suqian 223800, China
    3. Department of General Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China
  • Received:2021-08-11 Published:2022-04-25
  • Corresponding author: Chungen Xing
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

朱信强, 黄海龙, 蒋学通, 邢春根. 10 mm~20 mm非转移性直肠神经内分泌肿瘤完整切除率的多因素分析[J/OL]. 中华结直肠疾病电子杂志, 2022, 11(02): 163-167.

Xinqiang Zhu, Hailong Huang, Xuetong Jiang, Chungen Xing. Multifactor analysis of complete resection rate of 10 mm~20 mm nonmetastatic rectal neuroendocrine tumor[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(02): 163-167.

目的

探讨10 mm~20 mm非转移性直肠神经内分泌肿瘤组织完整切除率的影响因素。

方法

回顾分析徐州医科大学附属宿迁医院普外科和消化科2008年1月至2019年4月收治的直肠神经内分泌肿瘤患者的医院数据库数据，总结因素特点，对比分析内镜黏膜下切除与经肛切除组织完整性的影响因素，将有意义的因素，进行多因素分析，找出其独立危险因素。

结果

在24例患者中，诊断的中位年龄为43岁（29~58岁），62.5%为男性。距肛缘的中位距离为6.2 cm（3 cm~15 cm）。中位肿瘤直径大小为11.7 mm（10 mm~20 mm）。12例（50%）患者肿瘤浸润局限于黏膜层，有12例侵及黏膜下层。19例（79.17%）继续接受结肠镜随访，中位随访时间为37.3个月（3.5~113.0）。经肛局部切除组13例，完整切除率84.62%。内镜黏膜下切除11例，手术完整切除率54.55%。两组资料对比，术前超声肿块浸润深度、组织完整性切除，差异有统计学意义（χ2=2.542，2.663；P=0.028，0.046），对组织学切除完整性的比较，单因素分析侵犯深度、肿瘤大小、G分期、镜下表现是影响切除与否的危险因素，将有意义的单因素进行多因素分析，得出肿瘤浸润深度和肿瘤大小是其独立危险因素。

结论

对于10 mm~20 mm非转移性直肠神经内分泌肿瘤，肿瘤浸润深度和肿瘤大小是组织完整切除的独立危险因素。

关键词: 直肠, 非转移性, 直肠神经内分泌肿瘤, 完整切除, 因素分析
Objective

To investigate the factors influencing the tissue integrity resection rate of 10 mm~20 mm non-metastatic rectal neuroendocrine tumor.

Methods

The hospital database data of patients with rectal neuroendocrine tumor admitted to Department of General Surgery and Gastroenterology, Suqian Hospital, Xuzhou Medical University from January 2008 to April 2019 were retrospectively analyzed, and the characteristics of factors were summarized, to compare and analyze the influencing factors of tissue integrity between endoscopic submucosal resection and transanal resection, it will be meaningful to conduct multi-factor analysis to find out the independent risk factors.

Results

Of the 24 patients, the median age of diagnosis was 43 years (29 to 58 years) and 62.5% was male. The median distance from the anal border was 6.2 cm (3 cm~15 cm). The median tumor diameter was 11.7 mm (10 mm~20 mm).Tumor invasion was confined to the mucosal layer in 12 patients (50%), and the submucosal layer in 12 patients. The median follow-up time was 37.3 months (range 3.5~113.0). The complete resection rate was 84.62% in 13 patients. The complete resection rate was 54.55% in 11 cases. There were significant differences between the two groups (χ2=2.542, 2.663; P=0.028, 0.046). For the comparison of the integrity of histological resection, the invasion depth, tumor size, G stage and microscopic performance were the risk factors influencing the resection or not by univariate analysis, and the significant univariate analysis showed that tumor invasion depth and tumor size were the independent risk factors.

Conclusion

For 10 mm~20 mm non-metastatic rectal neuroendocrine tumors, the depth of tumor invasion and tumor size are independent risk factors for complete tissue resection.

Key words: Rectal, Non-metastasis, Rectal neuroendocrine tumor, Complete resection, Factor analysis
表1 患者的临床病理资料（例）
因素 结果
年龄（岁） 43（29~58）
性别

男

 15（62.5%）

女

 9（37.5%）
镜下表现

宽基底息肉样

 10

突出性肿块

 14
距肛缘距离（cm） 6.2（3~15）
治疗方法

经肛局部手术

 13

经内镜黏膜下切除

 11
肿瘤大小（mm） 11.7（10~20）
肿瘤分级

G1

 22

G2

 2
侵犯深度

黏膜层

 12

黏膜下层

 12
随访 19（79.17%）
随访时间（月） 37.3（3.5~113.0）
表2 两种治疗方式资料对比
因素 经肛局部手术（n=13） 内镜黏膜下切除（n=11） 检验值 P值
年龄 48.0（30~58） 50.0（29~57） Z=-1.697 0.465
性别 χ2=0.552 0.240

男

 5（38.46%） 10（90.91%）

女

 8（61.54%） 1（9.09%）
镜下表现 χ2=0.443 0.371

宽基底样息肉

 5（38.46%） 5（45.45%）

突出性肿块

 8（61.54%） 6（54.55%）
术前超声 χ2=2.542 0.028

黏膜层

 9 3

黏膜下层

 4 8
距肛门距离 6.7（3~8） 10.1（8~15） Z=-0.891 0.226
肿瘤大小 15.6（10~20） 11.9（10~19） Z=-0.251 0.522
整块切除 11（84.62%） 6（54.55%） χ2=2.663 0.046
不完整切除 2（15.38%） 5（45.45%） χ2=0.954 0.112
术后并发症 χ2=0.104 0.786

出血

 2 1

穿孔

 0 1
分级 χ2=0.087 0.943

G1

 12 10

G2

 1 1
表3 完整切除与否因素对比
因素 完整（n=17） 不完整（n=7） 检验值 P值
术式 χ2=0.914 0.123

经肛局部手术

 11 2

内镜黏膜下切除

 6 5
性别 χ2=0.633 0.789

男

 8 7

女

 9 0
年龄 49（29~58） 50（36~57） Z=-1.573 0.924
侵犯深度 χ2=3.114 0.015

黏膜层

 12 0

黏膜下层

 5 7
分级 χ2=3.016 0.004

G1

 15 7

G2

 2 0
肿瘤大小（mm） χ2=3.221 0.002

＜15

 11 2

≥15

 6 5
距肛门距离 9（3~15） 7（5~10） χ2=0.672 0.486
镜下表现 χ2=1.999 0.037

息肉

 9 1

肿块

 8 6
并发症 χ2=0.108 0.823

出血

 2 1

穿孔

 0 1

无

 15 5
表4 研究对象多因素分析结果
变量 β S.E， Wals df Sig. Exp（β） 95% CI
下限 上限
侵犯深度 2.916 1.377 4.467 1 .036 17.628 1.241 275.600
肿瘤大小 3.627 1.323 7.566 1 .008 39.783 2.719 439.068
[1]
Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors[J]. Cancer, 1997, 79(4): 813-829.
[2]
Scherubl H. Rectal carcinoids are on the rise: early detection by screening endoscopy[J].Endoscopy, 2009, 41(2): 162-165.
[3]
Gustafsson BI, Siddique L, Chan A, et al. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy[J]. International Journal of Oncology, 2008, 33(6): 1121-1131.
[4]
Kang H, O'Connell JB, Leonardi MJ, et al. Rare tumors of the colon and rectum: a national review[J]. Int J Colorectal Dis, 2007, 22(2): 183-189.
[5]
Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours[J]. Lancet Oncol, 2008, 9(1): 61-72.
[6]
Al Natour RH, Saund MS, Sanchez VM, et al. Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection[J]. J Gastrointest Surg, 2012, 16(3): 595-602.
[7]
Caplin M, Sundin A, Nillson O, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms[J]. Neuroendocrinology, 2012, 95(2): 88-97.
[8]
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors[J]. Cancer, 2003, 97(4): 934-959.
[9]
Ishikawa K, Arita T, Shimoda K, et al. Usefulness of transanal endoscopic surgery for carcinoid tumor in the upper and middle rectum[J]. Surg Endosc, 2005, 19(8): 1151-1154.
[10]
Onozato Y, Kakizaki S, Iizuka H, et al. Endoscopic treatment of rectal carcinoid tumors[J]. Dis Colon Rectum, 2010, 53(2): 169-176.
[11]
He L, Deng T, Luo H. Efficacy and safety of endoscopic resection therapies for rectal carcinoid tumors: a meta-analysis[J]. Yonsei Med J, 2015, 56(1): 72-81.
[12]
Fields AC, Saadat LV, Scully RE, et al. Local excision versus radical resection for 1- to 2-cm neuroendocrine tumors of the rectum: a national cancer database analysis [J]. Dis Colon Rectum, 2019, 62(4): 417-421.
[13]
Moon CM, Huh KC, Jung SA, et al. Long-term clinical outcomes of rectal neuroendocrine tumors according to the pathologic status after initial endoscopic resection: A KASID multicenter study[J]. Am J Gastroenterol, 2016, 111(9): 1276-1285.
[14]
Matsuhashi N, Takahashi T, Tomita H, et al. Evaluation of treatment for rectal neuroendocrine tumors sized under 20 mm in comparison with the WHO 2010 guidelines[J]. Mol Clin Oncol, 2017, 7(3): 476-480.
[15]
Rodrigues A, Castro-Pocas F, Pedroto I. Neuroendocrine rectal tumors: main features and management [J]. GE Port J Gastroenterol, 2015, 22(5): 213-220.
[16]
Chen WJ, Wu N, Zhou JL, et al. Full-thickness excision using transanal endoscopic microsurgery for treatment of rectal neuroendocrine tumors[J]. World J Gastroenterol, 2015, 21(30): 9142-9149.
[17]
Kumar AS, Coralic J, Kelleher DC, et al. Complications of transanal endoscopic microsurgery are rare and minor: a single institution's analysis and comparison to existing data[J]. Dis Colon Rectum, 2013, 56(3): 295-300.
[18]
Flexer SM, Durham-Hall AC, Steward MA, et al. TEMS: results of a specialist centre[J]. Surg Endosc, 2014, 28(6): 1874-1878.
[19]
Jernman J, Valimaki MJ, Louhimo J, et al. The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours[J]. Neuroendocrinology, 2012, 95(4): 317-324.
[20]
Konishi T, Watanabe T, Nagawa H, et al. Treatment of colorectal carcinoids: A new paradigm[J]. World J Gastrointest Surg, 2010, 2(5): 153-156.
[21]
Kulke MH, Shah MH, Benson AB, et al. Neuroendocrine tumors, version 1.2015[J]. J Natl Compr Canc Netw, 2015, 13(1): 78-108.
[22]
Kasuga A, Chino A, Uragami N, et al. Treatment strategy for rectal carcinoids: a clinicopathological analysis of 229 cases at a single cancer institution[J]. J Gastroenterol Hepatol, 2012, 27(12): 1801-1807.
[23]
McConnell YJ. Surgical management of rectal carcinoids: trends and outcomes from the Surveillance, Epidemiology, and End Results database (1988 to 2012) [J]. Am J Surg, 2016, 211(5): 877-885.
[24]
Shields CJ, Tiret E, Winter DC. Carcinoid tumors of the rectum: a multi-institutional international collaboration[J]. Ann Surg, 2010, 252(5): 750-755.
[25]
Weinstock B, Ward SC, Harpaz N, et al. Clinical and prognostic features of rectal neuroendocrine tumors[J]. Neuroendocrinology, 2013, 98(3): 180-187.
[26]
Ramage JK, De Herder WW, Delle Fave G, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms[J]. Neuroendocrinology, 2016, 103(2): 139-143.
[27]
Kulke MH, Benson AB, Bergsland E, et al. Neuroendocrine tumors[J]. J Natl Compr Canc Netw, 2012, 10(6): 724-764.
[1] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[2] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[3] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[4] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[5] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径＜1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[6] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[7] 庄宝雄, 邓海军. 单孔+1腹腔镜直肠癌侧方淋巴结清扫术[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 601-601.
[8] 张朝军, 袁新普. 腹腔镜辅助低位直肠癌根治术[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 602-602.
[9] 郑民华, 蒋天宇, 赵轩, 马君俊. 中国腹腔镜直肠癌根治术30年发展历程与未来[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 591-595.
[10] 池畔, 黄胜辉. 中国腹腔镜直肠癌根治术30年来的巨大进步[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 596-600.
[11] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[12] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[13] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[14] 王湛, 李文坤, 杨奕, 徐芳, 周敏思, 苏珈仪, 王亚丹, 吴静. 炎症指标在早发性结直肠肿瘤中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 802-810.
[15] 刘福成, 赵欣, 乔海朋, 刘晓峰, 张翀, 张宗明. 保留左结肠动脉的肠系膜下动脉根部淋巴结清扫对腹腔镜直肠癌根治术的疗效影响[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 647-653.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号